Evaluation of STARgraft-3 for Hemodialysis

This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft-3 hemodialysis access graft. STARgraft devices have been demonstrated in preclinical and other studies to have improved resistance to the common failure modes of venous anastomosis stenosis and infection. This study is an extension from prior studies with STARgraft AV (NCT03916731) and STARgraft-2 (NCT04783779) investigational devices. A previous study also included control implants of commercially available standard ePTFE grafts approved for the same use. The study is enrolling patients with End Stage Renal Disease (ESRD) requiring hemodialysis via a prosthetic vascular graft. The study proposes to evaluate the performance of the investigational STARgraft-3 compared to the ePTFE controls in the prior study and to published results, over a period of 6 months, with extended results to 1 year. Estimated enrollment is 15 subjects in this study.

NCT Number	NCT05729620
Lead Sponsor	Healionics Corporation
Conditions	End Stage Renal Disease
Enrollment	21 participants
Start Date	2022-11-29
Primary Completion	2024-02-02 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-27